Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update

Capricor Therapeutics NASDAQ: CAPR presented updated clinical data for deramiocel in Duchenne muscul

Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of it

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following t

U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a

FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIv

B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Ne

Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral t

U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext In

Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.

Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 da

– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3

Kaos Capital demands a governance reset and cash preservation at Capricor Therapeutics (NASDAQ: CAPR

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Kaos Capital Ltd. ("Kaos Capital," "we," or "us"), a significant and growing

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers i

Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular

Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash positio

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings

Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market

AMAT: -5% | Applied Materials shares are trading lower after the company reported Q3 financial resul

Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutra

Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results

Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on

Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session

Capricor Therapeutics (NASDAQ:CAPR) released second-quarter financial results and hosted an earnings

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.70) per share which missed the

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo

FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decis

Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overwei

Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular

US stocks gain, Dow up 300 points as tech shares surge 5.3%, Bristol-Myers Squibb beats expectation

US stocks rise with Nasdaq up 600 points, Dow up 0.69% and S&P 500 up 1.29%. Tech shares up 5%,

Capricor stock plunged after an FDA panel questioned Deramiocel's effectiveness in DMD despite p

Cantor Fitzgerald analyst Kristen Kluska downgrades Capricor Therapeutics (NASDAQ:CAPR) from Over

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos

Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-against-capricors-duchen

Martin Shkreli accuses Capricor Therapeutics of fraud and predicts legal action against its CEO and

FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends

Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consume

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos

Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Com

Capricor Therapeutics fell over 60% Monday after the FDA posted briefing documents ahead of the comp

Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's